• [Translated article] Successful Control of Recalcitrant Pruritus in Epidermolysis Bullosa Pruriginosa With Dupilumab
• "Quality of Life in Epidermolysis Bullosa" and "Epidermolysis Bullosa Burden of Disease": Italian translation, cultural adaptation, and pilot testing of two disease-specific questionnaires
• A Case of Dystrophic Epidermolysis Bullosa Responding to Oral Corticosteroids
• A case of dystrophic epidermolysis bullosa with a rare COL7A1 variant
• A case of intermediate recessive dystrophic epidermolysis bullosa with a novel COL7A1 mutation
• A scalable and cGMP-compatible autologous organotypic cell therapy for Dystrophic Epidermolysis Bullosa
• A short RNA molecule and tumour aggressiveness in people with epidermolysis bullosa
• Accelerated Aging and Microsatellite Instability in Recessive Dystrophic Epidermolysis Bullosa-Associated Cutaneous Squamous Cell Carcinoma
• Advances in Treatments for Epidermolysis Bullosa (EB): Emphasis on Stem Cell-Based Therapy
• Advantages of whole-exome sequencing over immunomapping in 67 Brazilian patients with epidermolysis bullosa
• An unusual cause of inguinal ulceration - dystrophic epidermolysis bullosa
• Antiviral drugs prolong survival in murine recessive dystrophic epidermolysis bullosa
• Beyond the Surface: A Narrative Review Examining the Systemic Impacts of Recessive Dystrophic Epidermolysis Bullosa
• Bone marrow transplantation and bone marrow-derived mesenchymal stem cell therapy in epidermolysis bullosa: A systematic review
• Chondroitin sulfate proteoglycan 4 (CSPG4) increases invasion of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma by modifying TGFbeta signaling
• Citrullinated Histone H3, a Marker for Neutrophil Extracellular Traps, Is Associated with Poor Prognosis in Cutaneous Squamous Cell Carcinoma Developing in Patients with Recessive Dystrophic Epidermolysis Bullosa
• Clinical-grade human skin-derived ABCB5+ mesenchymal stromal cells exert anti-apoptotic and anti-inflammatory effects <em>in vitro</em> and modulate mRNA expression in a cisplatin-induced kidney injury murine model
• Comprehensive orthodontic treatment using miniscrews and digital rehabilitation in a patient with severe recessive dystrophic epidermolysis bullosa
• Costs of UK community care for individuals with recessive dystrophic epidermolysis bullosa: Findings of the Prospective Epidermolysis Bullosa Longitudinal Evaluation Study
• Creation and characterization of novel rat model for recessive dystrophic epidermolysis bullosa: Frameshift mutation of the Col7a1 gene leads to severe blistered phenotype
• Current Treatment Landscape for Dystrophic Epidermolysis Bullosa: From Surgical Management to Emerging Gene Therapies and Novel Skin Grafts
• Cyclization-enhanced poly(β-amino ester)s vectors for efficient CRISPR gene editing therapy
• Descriptive Study of the Clinical and Molecular Features of Epidermolysis Bullosa Patients in a Romanian European Reference Network-Skin Affiliated Reference Center
• Diagnostic Challenges in a Family with Dominant Dystrophic Epidermolysis Bullosa and Isolated Hereditary Nail Disorder: Paternal Gonosomal Mosaicism for COL7A1 Mutation and Maternal RSPO4 Variant
• Dipeptidyl peptidase-4-mediated fibronectin processing evokes a pro-fibrotic extracellular matrix
• Dipeptidyl Peptidase-4-Mediated Fibronectin Processing Evokes a Profibrotic Extracellular Matrix
• Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ T helper 2 cells which may contribute to pruritus in lesional skin
• Dominant dystrophic epidermolysis bullosa is associated with glycolytically active GATA3+ Th2 cells which may contribute to pruritus in lesional skin
• Dystrophic Epidermolysis Bullosa (DEB): How Can Pregnancy Alter the Course of This Rare Disease? An Updated Literature Review on Obstetrical Management with an Additional Italian Experience
• Dystrophic epidermolysis bullosa characterized by mucosal lesions in a Chinese familial case with a novel compound heterozygous mutation of COL7A1
• Dystrophic epidermolysis bullosa: from disease biology to biologic therapy
• Dystrophic epidermolysis with dilation of esophageal stricture: A case report
• Efficacy of oral JAK1 or JAK1/2 inhibitor for treating refractory pruritus in dystrophic epidermolysis bullosa: A retrospective case series
• Elevated expression of interleukin-6 (IL-6) and serum amyloid A (SAA) in the skin and the serum of recessive dystrophic epidermolysis bullosa: Skin as a possible source of IL-6 through Toll-like receptor ligands and SAA
• Endoscopic balloon dilation of esophageal stricture in dystrophic epidermolysis bullosa patient: challenges faced and safety of procedure
• Epidemiological Characteristics of Inherited Epidermolysis Bullosa in an Eastern European Population
• Epidermolysis Bullosa
• Epidermolysis Bullosa Acquisita
• Epidermolysis Bullosa Dystrophica Inversa: Case Report of a Novel Genetic Mutation, Involving a Rare Genodermatoses
• Epidermolysis Bullosa Pruriginosa treated with baricitinib: A case report
• Epidermolysis Bullosa: Practical Clinical Tips From the Field
• Epidermolysis Bullosa: Two rare case reports of COL7A1 and EBS-GEN SEV KRT14 variants with review of literature
• Epidermolysis-Bullosa-Associated Squamous Cell Carcinomas Support an Immunosuppressive Tumor Microenvironment: Prospects for Immunotherapy
• Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa
• Exploring the Impact of Epidermolysis Bullosa on Parents and Caregivers: A Cross-Cultural Validation of the Epidermolysis Bullosa Burden of Disease Questionnaire
• Functional genotype-phenotype associations in recessive dystrophic epidermolysis bullosa
• Gamma-secretase inhibitors down-regulate the pro-fibrotic Notch signaling pathway in recessive dystrophic epidermolysis bullosa
• Gamma-Secretase Inhibitors Downregulate the Profibrotic NOTCH Signaling Pathway in Recessive Dystrophic Epidermolysis Bullosa
• Gene expression landscape of cutaneous squamous cell carcinoma progression
• Good clinical response to cemiplimab in a young patient with locally advanced cutaneous squamous cell carcinoma on preexisting recessive dystrophic epidermolysis bullosa
• Gross motor development in children with epidermolysis bullosa
• Health-related quality of life and clinical severity in people with epidermolysis bullosa - A proposal for assessing nutritional compromise by body mass index (Birmingham Epidermolysis Bullosa Severity Score)
• Hereditary epidermolysis bullosa: clinical-epidemiological profile of 278 patients at a tertiary hospital in Sao Paulo, Brazil
• Highlights of Gene and Cell Therapy for Epidermolysis Bullosa and Ichthyosis
• Highly efficient CRISPR/Cas9-mediated exon skipping for recessive dystrophic epidermolysis bullosa
• Histological and molecular restoration of type VII collagen in Recessive dystrophic epidermolysis bullosa mouse skin by topical injection of keratinocyte-like cells differentiated from human adipose-derived mesenchymal stromal cells
• Histone deacetylase inhibition mitigates fibrosis-driven disease progression in recessive dystrophic epidermolysis bullosa
• Identification of novel small molecule-based strategies of COL7A1 upregulation and readthrough activity for the treatment of recessive dystrophic epidermolysis bullosa
• IL-6 levels dominate the serum cytokine signature of severe epidermolysis bullosa: A prospective cohort study
• Increased healthcare burden and comorbidity risks of pediatric patients with dystrophic epidermolysis bullosa: Analysis of Nationwide Emergency Department Sample 2015-2019
• Induced pluripotent stem cell (iPSC) line MLi005-A derived from a patient with dominant dystrophic epidermolysis bullosa (DDEB)
• Intravenous gentamicin therapy induces functional type VII collagen in patients with recessive dystrophic epidermolysis bullosa: an open-label clinical trial
• Intravenous gentamicin therapy induces functional type VII collagen in recessive dystrophic epidermolysis bullosa patients: An open label clinical trial
• Involvement of Kindlin-1 in cutaneous squamous cell carcinoma
• Lipid Nanoparticles Efficiently Deliver the Base Editor ABE8e for COL7A1 Correction in Dystrophic Epidermolysis Bullosa Fibroblasts In Vitro
• Measuring the impact of pruritus in patients with epidermolysis bullosa: evaluation with an itch-specific instrument
• Mechanism underlying pruritus in recessive dystrophic epidermolysis bullosa: Role of interleukin-31 from mast cells and macrophages
• Methods for Decreasing Preweaning Mortality in a Fragile Mouse Model of Hypomorphic Collagen VII Deficiency
• Missense Variant c.3301C&gt;T (p.R1101W) in von Willebrand Factor A Sequence in a Patient with Recessive Dystrophic Epidermolysis Bullosa Pruriginosa with Compound Heterozygous <em>COL7A1</em> Variants
• Missense Variant c.3301C>T (p.R1101W) in von Willebrand Factor A Sequence in a Patient with Recessive Dystrophic Epidermolysis Bullosa Pruriginosa with Compound Heterozygous COL7A1 Variants
• Molecular profiling of an Indian EB cohort - a single centre experience
• Novel variant c.7795-1G>A of COL7A1 gene in a 12-month-old female child with recessive dystrophic epidermolysis bullosa treated with dupilumab
• Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa
• Oleogel-S10 in Dystrophic Epidermolysis Bullosa: A Case Series Evaluating the Impact on Wound Burden Over Two Years
• Online, home-based dystrophic epidermolysis bullosa registry
• Oral prosthetic rehabilitation in patients with Epidermolysis Bullosa Hereditaria: a systematic review
• Patients suffering from dystrophic epidermolysis bullosa are prone to developing autoantibodies against skin proteins: A longitudinal confirmational study
• Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa
• Practical Tips on Epidermolysis Bullosa for Caregivers: Part 2
• Pruritus Anesis in Dystrophic Epidermolysis Bullosa Pruriginosa with Dupilumab
• Reconstruction with free jejunal flap in dystrophic epidermolysis bullosa complicated with hypopharyngeal cancer: A case report
• Regenerative medicine in the treatment of specific dermatologic disorders: a systematic review of randomized controlled clinical trials
• Renal Amyloidosis in a Child with Recessive Dystrophic Epidermolysis Bullosa Due to a Novel Variant in COL7A1 Gene
• Revolutionary breakthrough: FDA approves Vyjuvek, the first topical gene therapy for dystrophic epidermolysis bullosa
• Self-improving dystrophic epidermolysis bullosa with a novel heterozygous missense variant in the COL7A1 gene in a Taiwanese family
• Simple and affordable soft brace application in dystrophic epidermolysis bullosa patients
• Splice modulation strategy applied to deep intronic variants in COL7A1 causing recessive dystrophic epidermolysis bullosa
• Splicing Modulation via Antisense Oligonucleotides in Recessive Dystrophic Epidermolysis Bullosa
• Stopping a runaway train: targeting fibrosis in recessive dystrophic epidermolysis bullosa
• Successful treatment of multicentric Castleman's disease associated with dystrophic epidermolysis bullosa using anti-interleukin-6 receptor antibody
• Systematic review on antipruritic therapies for patients with Epidermolysis bullosa
• Th2 response drives itch in dystrophic epidermolysis bullosa pruriginosa: A case-control study
• Therapies for cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa: a systematic review of 157 cases
• Treatment of Epidermolysis Bullosa and Future Directions: A Review
• Twin Prime Editing Mediated Exon Skipping/Reinsertion for Restored Collagen VII Expression in Recessive Dystrophic Epidermolysis Bullosa
• Two sisters with recessive dystrophic epidermolysis bullosa caused by novel variants in COL7A1
• Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa
• Unusual presentation of cutaneous myiasis in the knee: case report
• Unveiling the value of C-reactive protein as a severity biomarker and the IL4/IL13 pathway as a therapeutic target in recessive dystrophic epidermolysis bullosa: A multiparametric cross-sectional study
• Wound behavior in dystrophic epidermolysis bullosa: A retrospective natural history case series